These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 4636483)

  • 1. [Organization of provision of medical and technical laboratory products by the pharmaceutical services].
    Görtz D
    Pharmazie; 1972 Oct; 27(10):Suppl 10:224-3. PubMed ID: 4636483
    [No Abstract]   [Full Text] [Related]  

  • 2. [Application of economic agreements relating to drug products].
    Fritsch O; Gueinzius E
    Pharm Prax; 1972; 9():Suppl 9:199-20. PubMed ID: 5086344
    [No Abstract]   [Full Text] [Related]  

  • 3. [Drug provision in an extensive rural district using a "mobile drug dispenser"].
    Herold JE
    Pharm Prax; 1972; 9():Suppl 9:210-3. PubMed ID: 5086347
    [No Abstract]   [Full Text] [Related]  

  • 4. Reimbursement of drug cost-medical assistance program.
    Hosp Formul; 1975 Mar; 10(3):120, 122, 142. PubMed ID: 10297178
    [No Abstract]   [Full Text] [Related]  

  • 5. Health care cost control by third party payors: fee schedules and the Sherman Act.
    Kallstrom DW
    Duke Law J; 1978 May; (2):645-97. PubMed ID: 10239068
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug services and costs in HMO prototypes.
    Johnson RE; Campbell WH
    Am J Hosp Pharm; 1973 May; 30(5):405-21. PubMed ID: 4704420
    [No Abstract]   [Full Text] [Related]  

  • 7. Can health care costs be contained? Yes, says one third party fiscal intermediary.
    Kaplan SX
    Empl Benefits J; 1978; 3(4):10-3, 15. PubMed ID: 10294880
    [No Abstract]   [Full Text] [Related]  

  • 8. [Basic principles of accounting and statistics and their use in the pharmaceutical and medical technology supply service].
    Mittag D
    Pharm Prax; 1972; 12():280-8. PubMed ID: 4665802
    [No Abstract]   [Full Text] [Related]  

  • 9. [Technical, organizational and medical problems in serial x-ray examinations].
    Zutz HU
    Rontgenpraxis; 1973 Feb; 26(2):29-43. PubMed ID: 4693727
    [No Abstract]   [Full Text] [Related]  

  • 10. Reengineering the retail/ambulatory pharmacy for provision of biotechnology pharmaceutical services.
    Schneider PJ
    Pharm Pract Manag Q; 1998 Jul; 18(2):32-6. PubMed ID: 10185237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The device industry in Germany.
    Schmitt JM
    Med Device Technol; 1997 Nov; 8(9):36. PubMed ID: 10174628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Calculation and evaluation of medical prescriptions by mechanical data processing].
    Bretschneider K; Voss H
    Pharm Prax; 1969; 8():Suppl 8:169+. PubMed ID: 5348227
    [No Abstract]   [Full Text] [Related]  

  • 13. Maximum allowable cost for drugs.
    Hosp Formul; 1975 Mar; 10(3):116, 119-20. PubMed ID: 10237830
    [No Abstract]   [Full Text] [Related]  

  • 14. Abolition of Pharmaceutical Reimbursement Advisory Committee: final regulation.
    Fed Regist; 1978 Aug; 43(154):35310-1. PubMed ID: 10297140
    [No Abstract]   [Full Text] [Related]  

  • 15. Distribution and cost of drugs in a pharmaceutically decentralized health maintenance organization.
    Hardigan WD; Slywka GW; Eng HJ
    Contemp Pharm Pract; 1980; 3(1):23-30. PubMed ID: 10245109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugs in national health insurance: an effective cost containment mechanism.
    Hoff LC
    Hosp Formul; 1978 Jul; 13(7):528-9, 532, 534. PubMed ID: 10308291
    [No Abstract]   [Full Text] [Related]  

  • 17. [Assistance for medicine for pensioners. Requirements for and utilization of supplementary assistance for medicine by patients referred for long-term medical assessment].
    Hilden J
    Ugeskr Laeger; 1981 Mar; 143(10):646-9. PubMed ID: 7281272
    [No Abstract]   [Full Text] [Related]  

  • 18. The effects of cost sharing on the demand for prescription drugs in Belgium.
    van Doorslaer E
    Acta Hosp; 1984; 24(3):69-81. PubMed ID: 10268808
    [No Abstract]   [Full Text] [Related]  

  • 19. NHI drug costs may reach $18 billion.
    Small WE
    Am Pharm; 1980 Jan; NS20(1):17. PubMed ID: 7369114
    [No Abstract]   [Full Text] [Related]  

  • 20. The cost of the district hospital: a case study in Malawi.
    Mills AJ; Kapalamula J; Chisimbi S
    Bull World Health Organ; 1993; 71(3-4):329-39. PubMed ID: 8324852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.